How have Polynovo shares been performing since leaving the ASX 200?

The medical device company's shares can't seem to catch a break this week.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Polynovo shares are edging 1.15% lower to $1.295 on Tuesday
  • While no company announcements have been made, Polynovo shares were removed from the ASX 200 on Monday
  • The quarterly rebalance forces fund managers to adjust their portfolios to adhere to operating mandates, which in turn can put buying or selling pressure on particular shares

The Polynovo Ltd (ASX: PNV) share price is heading south again today despite the company not releasing any announcements.

Since the start of the week, the medical device company's shares are down 3% to currently trade at $1.295 each.

While down 1.15% today, this isn't the case for the S&P/ASX 200 Index (ASX: XJO) which is 1.59% higher to 6,535 points at the time of writing.

Let's take a look at what is weighing down the Polynovo share price of late.

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

What's impacting Polynovo shares?

Besides the recent buying action by the company's board, it has been relatively quiet for Polynovo.

Its last trading update came in early April when management provided a snapshot of the company's third-quarter results.

Since then, Polynovo shares tumbled to a multi-year low of 83.5 cents before rebounding to February 2022 levels.

The share price weakness came off the back of negative investor sentiment across the ASX following fears surrounding a possible recession.

However, added to the mix is the large number of short-sellers on Polynovo's registry.

The latest short position report by the Australian Securities & Investments Commission (ASIC) reveals the level of short interest within companies.

Polynovo remains in the top 10 of short interest ASX stocks, with 10.95% of its shares being shorted by investors.

In case you aren't aware, short-selling is a common trading strategy that aims to profit from the fall in the price of a security. The goal is for an investor to borrow shares then sell them and buy them back at a lower price for a profit.

On top of this, the S&P/ASX 200 Healthcare (ASX: XHJ) sector has fallen by 4.63% in the past week and is down 15% in 2022.

Yet perhaps the biggest selling pressure has come from Polynovo's removal from the S&P/ASX 200 Index (ASX: XJO) which took effect on Monday.

The S&P Dow Jones Indices announced changes in its quarterly rebalance earlier this month.

Polynovo's removal from the ASX 200 means that fund managers must abide by their investing mandate which permits them to only buy shares included in specific indices. It's commonplace that shares can climb or fall after being included in or excluded from a particular index.

Polynovo share price summary

While staging a small rebound from early May onwards, the Polynovo share price is down 15% year-to-date.

When looking at the past 12 months, its shares are deep in the red by 53%.

Based on today's price, Polynovo presides a market capitalisation of about $856 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two ASX share investors sharing a secret.
Healthcare Shares

Cochlear shares are quietly rebounding: Is a bigger rally coming?

After a 58% plunge, Cochlear doesn’t need perfection to surprise investors.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech is tipped to more than double in value

Encouraging trial results have the analysts excited.

Read more »

person climbing mountain
Healthcare Shares

CSL share price forecast: How high could it climb in the next year?

CSL shares could roar back, but investors need more than hope.

Read more »

Two CEOs shaking hands on a deal.
Healthcare Shares

Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

Read more »

Woman looking at stock market numbers.
Healthcare Shares

CSL shares are rising: 3 things investors need to watch

CSL’s FY26 result could reveal whether the turnaround has finally begun.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »